ARTIVION INC (AORT) Stock Fundamental Analysis
NYSE:AORT - New York Stock Exchange, Inc. - US2289031005 - Common Stock - Currency: USD
AORT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. AORT has an average financial health and profitability rating. AORT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AORT has reported negative net income.
AORT had a positive operating cash flow in the past year.
AORT had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: AORT reported negative operating cash flow in multiple years.
1.2 Ratios
AORT has a Return On Assets of -1.69%. This is in the better half of the industry: AORT outperforms 70.90% of its industry peers.
With a decent Return On Equity value of -4.84%, AORT is doing good in the industry, outperforming 71.43% of the companies in the same industry.
AORT has a Return On Invested Capital of 2.94%. This is in the better half of the industry: AORT outperforms 73.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.69% | ||
| ROE | -4.84% | ||
| ROIC | 2.94% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.47%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AORT's Operating Margin of 6.92% is fine compared to the rest of the industry. AORT outperforms 74.60% of its industry peers.
In the last couple of years the Operating Margin of AORT has grown nicely.
The Gross Margin of AORT (64.03%) is better than 65.61% of its industry peers.
AORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.92% | ||
| PM (TTM) | N/A | ||
| GM | 64.03% |
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
AORT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for AORT has been increased compared to 1 year ago.
AORT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AORT is higher compared to a year ago.
2.2 Solvency
AORT has an Altman-Z score of 2.03. This is not the best score and indicates that AORT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.03, AORT is in the better half of the industry, outperforming 60.85% of the companies in the same industry.
AORT has a debt to FCF ratio of 28.76. This is a negative value and a sign of low solvency as AORT would need 28.76 years to pay back of all of its debts.
AORT has a Debt to FCF ratio of 28.76. This is in the better half of the industry: AORT outperforms 69.31% of its industry peers.
A Debt/Equity ratio of 1.15 is on the high side and indicates that AORT has dependencies on debt financing.
AORT's Debt to Equity ratio of 1.15 is on the low side compared to the rest of the industry. AORT is outperformed by 78.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.15 | ||
| Debt/FCF | 28.76 | ||
| Altman-Z | 2.03 |
ROIC/WACC0.35
WACC8.34%
2.3 Liquidity
A Current Ratio of 4.34 indicates that AORT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.34, AORT is in the better half of the industry, outperforming 70.90% of the companies in the same industry.
AORT has a Quick Ratio of 3.15. This indicates that AORT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AORT (3.15) is better than 65.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.34 | ||
| Quick Ratio | 3.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.89% over the past year.
Looking at the last year, AORT shows a quite strong growth in Revenue. The Revenue has grown by 9.75% in the last year.
The Revenue has been growing slightly by 7.06% on average over the past years.
EPS 1Y (TTM)41.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-290%
Revenue 1Y (TTM)9.75%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%3.88%
3.2 Future
AORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 74.69% yearly.
AORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.90% yearly.
EPS Next Y136.53%
EPS Next 2Y74.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.07%
Revenue Next 2Y9.41%
Revenue Next 3Y9.9%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AORT. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 153.93 indicates a quite expensive valuation of AORT.
Based on the Price/Forward Earnings ratio, AORT is valued a bit cheaper than 65.61% of the companies in the same industry.
AORT is valuated expensively when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 153.93 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AORT indicates a somewhat cheap valuation: AORT is cheaper than 71.43% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AORT is valued a bit cheaper than 69.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 92.03 | ||
| EV/EBITDA | 25.08 |
4.3 Compensation for Growth
AORT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AORT's earnings are expected to grow with 74.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
AORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.18
-0.53 (-2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners85.43%
Inst Owner ChangeN/A
Ins Owners5.47%
Ins Owner Change4.36%
Market Cap1.02B
Analysts86.67
Price Target32.98 (36.39%)
Short Float %10.57%
Short Ratio10.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-257.33%
Min EPS beat(2)-537.25%
Max EPS beat(2)22.6%
EPS beat(4)2
Avg EPS beat(4)-113.97%
Min EPS beat(4)-537.25%
Max EPS beat(4)168.88%
EPS beat(8)4
Avg EPS beat(8)-108.55%
EPS beat(12)8
Avg EPS beat(12)-41%
EPS beat(16)10
Avg EPS beat(16)-57.97%
Revenue beat(2)0
Avg Revenue beat(2)-3.14%
Min Revenue beat(2)-5.37%
Max Revenue beat(2)-0.91%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-5.37%
Max Revenue beat(4)3.85%
Revenue beat(8)5
Avg Revenue beat(8)0.8%
Revenue beat(12)7
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)7.36%
PT rev (1m)-2.51%
PT rev (3m)-2.51%
EPS NQ rev (1m)-157.78%
EPS NQ rev (3m)-157.78%
EPS NY rev (1m)11.33%
EPS NY rev (3m)11.33%
Revenue NQ rev (1m)-9.2%
Revenue NQ rev (3m)-9.2%
Revenue NY rev (1m)-1.53%
Revenue NY rev (3m)-1.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 153.93 | ||
| P/S | 2.62 | ||
| P/FCF | 92.03 | ||
| P/OCF | 45.73 | ||
| P/B | 3.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.08 |
EPS(TTM)-0.43
EYN/A
EPS(NY)0.16
Fwd EY0.65%
FCF(TTM)0.26
FCFY1.09%
OCF(TTM)0.53
OCFY2.19%
SpS9.24
BVpS6.57
TBVpS-2.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.69% | ||
| ROE | -4.84% | ||
| ROCE | 3.72% | ||
| ROIC | 2.94% | ||
| ROICexc | 3.17% | ||
| ROICexgc | 7.82% | ||
| OM | 6.92% | ||
| PM (TTM) | N/A | ||
| GM | 64.03% | ||
| FCFM | 2.84% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.47%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y37.89%
ROICexcg growth 5Y4.3%
ROICexc growth 3Y45.07%
ROICexc growth 5Y7.68%
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.15 | ||
| Debt/FCF | 28.76 | ||
| Debt/EBITDA | 6.21 | ||
| Cap/Depr | 46.22% | ||
| Cap/Sales | 2.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 43.53% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.34 | ||
| Quick Ratio | 3.15 | ||
| Altman-Z | 2.03 |
F-Score4
WACC8.34%
ROIC/WACC0.35
Cap/Depr(3y)42.06%
Cap/Depr(5y)43.23%
Cap/Sales(3y)2.8%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-290%
EPS Next Y136.53%
EPS Next 2Y74.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.75%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%3.88%
Revenue Next Year8.07%
Revenue Next 2Y9.41%
Revenue Next 3Y9.9%
Revenue Next 5YN/A
EBIT growth 1Y62.95%
EBIT growth 3Y43.36%
EBIT growth 5Y12.95%
EBIT Next Year106.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.05%
FCF growth 3YN/A
FCF growth 5Y7.33%
OCF growth 1Y18.12%
OCF growth 3YN/A
OCF growth 5Y7.04%